CEEU

Morning bid: heading for recession

Morning bid: heading for recession

An employee completes a sales display at a Naturalia organic food supermarket operated by Casino Group, following the outbreak of the coronavirus disease (COVID-19), in Bretigny-sur-Orge, near Paris, France, July 30 2020. REUTERS/ Benoitt Tessier Register now for FREE unlimited access to Reuters.com Register A Day ahead of Anshuman Daga’s European and Global Markets Will …

Morning bid: heading for recession Read More »

Morning bid: China is calming down again, Jackson Hole looms

Morning bid: China is calming down again, Jackson Hole looms

People pass an electronic screen displaying Japan’s Nikkei stock price index in a conference hall in Tokyo, Japan June 14, 2022. REUTERS/Issei Kato Register now for FREE unlimited access to Reuters.com Register Aug 22 (Reuters) – A look at Jamie McGeever’s day ahead in Asian markets Business and macro agendas in Asia are remarkably light …

Morning bid: China is calming down again, Jackson Hole looms Read More »

Stocks choppy, US yields fall as investors digest Fed minutes

Stocks choppy, US yields fall as investors digest Fed minutes

A man in a protective mask walks past an electronic board displaying the Shanghai Composite Index, Nikkei Index, and Dow Jones Industrial Average during the coronavirus disease (COVID-19) outbreak outside a real estate agency in Tokyo, Japan, March 7, 2022. REUTERS / Kim Kyung Hoon Register now for FREE unlimited access to Reuters.com Register Wall …

Stocks choppy, US yields fall as investors digest Fed minutes Read More »

Bluebird's $2.8M Gene Therapy Becomes Most Expensive Drug After U.S. Approval

Bluebird’s $2.8M Gene Therapy Becomes Most Expensive Drug After U.S. Approval

Signage is on display outside the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, US, Aug. 29, 2020. REUTERS/Andrew Kelly/File Photo Register now for FREE unlimited access to Reuters.com Register Aug 17 (Reuters) – The U.S. Food and Drug Administration on Wednesday approved bluebird bios (BLUE.O) gene therapy for patients with a rare …

Bluebird’s $2.8M Gene Therapy Becomes Most Expensive Drug After U.S. Approval Read More »